Suk J. Oh
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.
Journal: International journal of cancer
Published: October 03, 2024
Risk of malignant lymphoma in patients with previous tuberculosis infection: a cohort study.
Journal: Annals of hematology
Published: August 28, 2024
Radioimmunotherapy with 131 I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma.
Journal: Asia-Pacific journal of clinical oncology
Published: November 02, 2022
Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).
Journal: British journal of haematology
Published: August 02, 2019
Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia.
Journal: Cancer medicine
Published: November 08, 2017
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 12, 2017
Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.
Journal: Leukemia & lymphoma
Published: December 16, 2015
Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen.
Journal: Annals of hematology
Published: January 05, 2015
CTRP1 protects against diet-induced hyperglycemia by enhancing glycolysis and fatty acid oxidation.
Journal: The Journal of nutritional biochemistry
Published: December 18, 2014
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
Journal: Haematologica
Published: April 08, 2014
Anti-leukemic effect of 2-pyrone derivatives via MAPK and PI3 kinase pathways.
Journal: Investigational new drugs
Published: February 03, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026